Denali Therapeutics Inc. (DNLI)

NASDAQ

$17.35

-$0.63 (3.50%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$17.22$18.17

Open $18.05

52 Week Range

$10.57$24.34

Previous Close $17.98

Market Cap2.54B

Volume1.26M

Avg Volume2.18M

P/E (TTM)-6.00

EPS (TTM)$-2.89

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Denali Therapeutics Inc.

DEC102025

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Source: GlobeNewsWire•6 days ago

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per shar...

DEC92025

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Source: GlobeNewsWire•6 days ago

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre...

DEC42025

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Source: GlobeNewsWire•11 days ago

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of...

DEC42025

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Source: GlobeNewsWire•11 days ago

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of ...

NOV62025

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Source: GlobeNewsWire•39 days ago

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided business highlights....

OCT132025

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Source: GlobeNewsWire•63 days ago

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seekin...